BACKGROUND: Systolic heart failure (SHF) and chronic obstructive pulmonary disease (COPD) are frequently associated. The purpose of our study was to explore the impact of COPD severity on symptoms and prognosis in patients with SHF. METHODS AND RESULTS: Chronic obstructive pulmonary disease was systematically screened by spirometry in 348 patients admitted for SHF from April 2002 to December 2006. Severity of COPD was defined according to the GOLD classification. Prevalence of COPD was 37.9 %. Patients' distribution according to GOLD stages I, II, II and IV were, respectively, 51.5, 37.9, 7.6 and 3.0 %. Severity of dyspnoea increases with GOLD stage. There was a significant correlation between NYHA stage and left ventricular ejection fraction in patients without COPD (R (2) = 0.03; P = 0.01) but not in patients with COPD. Mean follow-up was of 54.9 ± 27.4 months. Mortality was 46.6 % and was highest in the COPD group (53.8 vs. 42.3 %; P = 0.049). Kaplan-Meier survival curves showed that patients with GOLD stage I had the same prognosis than patients without COPD and mortality increased from GOLD stage II to stage IV. After multivariate analysis, GOLD stage and diuretics' dose were independently associated with mortality. CONCLUSIONS: Chronic obstructive pulmonary disease is frequent in patients with SHF and increases mortality. Since dyspnoea is poorly specific of COPD in chronic heart failure patients, COPD remains underdiagnosed thus leading to inappropriate increase of diuretics' dose. COPD should be systematically screened in patients with SHF to adapt prescription of selective β1-blockers, and diuretics' dose and reduce the exposition to risk factors.
BACKGROUND:Systolic heart failure (SHF) and chronic obstructive pulmonary disease (COPD) are frequently associated. The purpose of our study was to explore the impact of COPD severity on symptoms and prognosis in patients with SHF. METHODS AND RESULTS:Chronic obstructive pulmonary disease was systematically screened by spirometry in 348 patients admitted for SHF from April 2002 to December 2006. Severity of COPD was defined according to the GOLD classification. Prevalence of COPD was 37.9 %. Patients' distribution according to GOLD stages I, II, II and IV were, respectively, 51.5, 37.9, 7.6 and 3.0 %. Severity of dyspnoea increases with GOLD stage. There was a significant correlation between NYHA stage and left ventricular ejection fraction in patients without COPD (R (2) = 0.03; P = 0.01) but not in patients with COPD. Mean follow-up was of 54.9 ± 27.4 months. Mortality was 46.6 % and was highest in the COPD group (53.8 vs. 42.3 %; P = 0.049). Kaplan-Meier survival curves showed that patients with GOLD stage I had the same prognosis than patients without COPD and mortality increased from GOLD stage II to stage IV. After multivariate analysis, GOLD stage and diuretics' dose were independently associated with mortality. CONCLUSIONS:Chronic obstructive pulmonary disease is frequent in patients with SHF and increases mortality. Since dyspnoea is poorly specific of COPD in chronic heart failurepatients, COPD remains underdiagnosed thus leading to inappropriate increase of diuretics' dose. COPD should be systematically screened in patients with SHF to adapt prescription of selective β1-blockers, and diuretics' dose and reduce the exposition to risk factors.
Authors: K K Iversen; J Kjaergaard; D Akkan; L Kober; C Torp-Pedersen; C Hassager; J Vestbo; E Kjoller Journal: J Intern Med Date: 2008-06-05 Impact factor: 8.989
Authors: Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni Journal: Eur J Heart Fail Date: 2009-01-27 Impact factor: 15.534
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Frank Edelmann; Raoul Stahrenberg; Götz Gelbrich; Kathleen Durstewitz; Christiane E Angermann; Hans-Dirk Düngen; Thomas Scheffold; Christian Zugck; Bernhard Maisch; Vera Regitz-Zagrosek; Gerd Hasenfuss; Burkert M Pieske; Rolf Wachter Journal: Clin Res Cardiol Date: 2011-03-17 Impact factor: 5.460
Authors: Tadeusz Osadnik; Jarosław Wasilewski; Andrzej Lekston; Joanna Strzelczyk; Anna Kurek; Aleksander Rafał Gutowski; Krzysztof Dyrbuś; Kamil Bujak; Rafał Reguła; Piotr Rozentryt; Bożena Szyguła-Jurkiewicz; Lech Poloński Journal: Clin Res Cardiol Date: 2014-03-09 Impact factor: 5.460
Authors: Ovidiu Chioncel; Sean P Collins; Stephen J Greene; Peter S Pang; Andrew P Ambrosy; Elena-Laura Antohi; Muthiah Vaduganathan; Javed Butler; Mihai Gheorghiade Journal: Card Fail Rev Date: 2017-11
Authors: Armine G Minasian; Frank Jj van den Elshout; Pn Richard Dekhuijzen; Petra Je Vos; Frank F Willems; Paul Jpc van den Bergh; Yvonne F Heijdra Journal: Transl Respir Med Date: 2014-09-25